Abstract Details

Title Associations Between Serum Biomarkers, Social Factors, and ASCVD Scores in African American Men: Interim Analysis from an Ongoing Clinical Trial

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 4-006

Objective This study examined associations among Atherosclerotic Cardiovascular Disease (ASCVD) risk scores, serum biomarkers, sociodemographic, and clinical factors in Black men with prior stroke or transient ischemic attack (TIA).

Background Stroke remains a leading cause of mortality and disability in the United States, with African American individuals disproportionately affected.

Design/Methods This cross-sectional analysis used baseline data from an ongoing 6-month prospective randomized controlled trial (RCT) evaluating the effects of a stroke risk reduction program, TargEted MAnageMent Intervention (TEAM), versus a waitlist control among 160 Black men with a history of stroke or TIA within the past 10 years. Demographic variables included age, education, marital status, living status, and health insurance coverage. Contextual variables included perceived stress (PSS-10), discrimination, and health literacy using validated scales. Stroke risk was estimated using a combination of ASCVD scores as well as serum biomarker and clinical targets per American Heart Association/American Stroke Association guidelines. Associations between sociodemographic, serum biomarker, and ASCVD variables were assessed using point biserial correlations.

Results The analyzed sample (n=62) had a mean age of 61.40 years (SD=9.65) and a mean time since stroke/TIA of 32.14 months (SD=27.79). Mean LDL was 81.02 mg/dL (SD=36.90), HbA1c 6.54% (SD=1.25), and BMI 30.50 kg/m² (SD=7.43). Seventy percent were diagnosed with hypertension, and 17.74% were current smokers.
Higher ASCVD scores (≥20%) were associated with older age (r=0.55, p<0.001) and Medicare coverage (r=0.36, p=0.004). Elevated LDL (>70 mg/dL) was associated with not having Medicare and private insurance (r=−0.27, p=0.04). Smoking was related to fewer years of education (r=−0.25, p=0.047) and higher perceived stress (r=0.29, p=0.023). Hypertension (SBP>130 mmHg) was associated with fewer people in the household (r=−0.30, p=0.016).

Conclusions Risk of stroke recurrence among Black men is influenced by demographic and contextual factors, underscoring the need for a comprehensive approach to risk assessment and management.

Authors/Disclosures
Ameena Shafiq, MD PRESENTER	Dr. Shafiq has nothing to disclose.
Rajeet Shrestha	Rajeet Shrestha has received personal compensation in the range of $500-$4,999 for serving as a Speaker for CME program with Clinical Care Options .
Carolyn Still, PhD	Dr. Still has nothing to disclose.
Christopher J. Burant, PhD	Prof. Burant has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AMOS Corporation. The institution of Prof. Burant has received research support from NIH. The institution of Prof. Burant has received research support from VA.
Jessica Surdam, MPH	Ms. Surdam has nothing to disclose.
Douglas Einstadter, MD	The institution of Dr. Einstadter has received research support from CDC. The institution of Dr. Einstadter has received research support from Ohio Department of Medicaid. The institution of Dr. Einstadter has received research support from NIMH. The institution of Dr. Einstadter has received research support from NINR. The institution of Dr. Einstadter has received research support from AHRQ. The institution of Dr. Einstadter has received research support from HRSA.
Nicole M. Fiorelli, MA	Ms. Fiorelli has nothing to disclose.
Jacqueline Krehel-Montgomery, BA	Mrs. Krehel-Montgomery has nothing to disclose.
Beth Lute, MS	Ms. Lute has nothing to disclose.
Sophia Sundararajan, MD (University Hospitals of Cleveland)	Dr. Sundararajan has stock in Boston Scientific Corp. Dr. Sundararajan has stock in Cisco Systems. Dr. Sundararajan has stock in Coca Cola Co. Dr. Sundararajan has stock in Cummins Inc. Dr. Sundararajan has stock in Hartford Insurance group. Dr. Sundararajan has stock in Johnson and Johnson. Dr. Sundararajan has stock in Merck and Company Inc. Dr. Sundararajan has stock in Microsoft. Dr. Sundararajan has stock in Netflix. Dr. Sundararajan has stock in Novartis. Dr. Sundararajan has stock in Oracle Corp. Dr. Sundararajan has stock in Pepsico. Dr. Sundararajan has stock in Proctor and Gamble. Dr. Sundararajan has stock in Qualcomm Inc. Dr. Sundararajan has stock in Travelers Cos Inc. Dr. Sundararajan has stock in Vertex Pharmacueticals. Dr. Sundararajan has stock in Visa Inc. Dr. Sundararajan has stock in Wallmart. Dr. Sundararajan has stock in Zoetis Inc Cl A. The institution of Dr. Sundararajan has received research support from NIH. The institution of Dr. Sundararajan has received research support from AHA.
MARTHA SAJATOVIC, MD	Dr. SAJATOVIC has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck, Janssen, Teva, Otsuka, Alkermes. The institution of Dr. SAJATOVIC has received research support from Neurelis, Intra-Cellular, Merck, Otsuka, Alkermes, International Society for Bipolar Disorders (ISBD), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), . Dr. SAJATOVIC has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��